Mesoblast (NASDAQ: MESO) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.
Insider & Institutional Ownership
2.7% of Mesoblast shares are held by institutional investors. Comparatively, 3.7% of CASI Pharmaceuticals shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 24.5% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Mesoblast and CASI Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mesoblast||$2.41 million||241.67||-$76.81 million||($0.78)||-7.94|
|CASI Pharmaceuticals||$50,000.00||5,382.30||-$9.45 million||($0.15)||-25.66|
CASI Pharmaceuticals has lower revenue, but higher earnings than Mesoblast. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Mesoblast has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Mesoblast and CASI Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mesoblast currently has a consensus price target of $14.25, indicating a potential upside of 130.21%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 10.39%. Given Mesoblast’s higher possible upside, analysts clearly believe Mesoblast is more favorable than CASI Pharmaceuticals.
This table compares Mesoblast and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.